\
&
Contact us
\
&
Contact us
The Partnership will create a transformative R&I programme between social sciences and humanities to enable inclusive sustainable development and social and economic resilience in the light of changes in climate, technology, demography and global trade patterns, and potential unexpected shocks.
- The draft proposal of the Partnership is accessible here.
- DLR Projektträger is commissioned by HERA Humanities in the European Research Area to conduct foresight exercises to lay the groundwork for the Strategic Research and Innovation Agenda for the European Partnership on Social Transformations and Resilience.Until April 2026, different partners will draw out the future strategic research & innovation agenda for tihs partnership. You can join the collaborative platform that helps co-create this strategic agenda.
- The future Partnership will be coordinated by NCN - National Science Centre, Poland. NCN provides further information on the Partnership via the CHANSE website. While DLR Projektträger facilitates the co-creation of a strategic research agenda, NCN takes care of the process of building a consortium of funding organisations and public authorities for the new EU Partnership.
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
manhei.to@fwo.be
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
